Daxor debuts FDA-cleared BVA analyzer at HFSA meeting

Daxor (DXR) Corporation announces significant commercial momentum and clinical validation following the Heart Failure Society of America Annual Scientific Meeting. The company’s debut of its newly FDA-cleared, next-generation BVA analyzer signals a new era of data-driven fluid management for a multi-billion-dollar market. The initial response from clinicians confirmed robust market demand for the new system, driven by its enhanced ease of use, speed, and over 95% accuracy. During the meeting, new clinical data presented from three leading institutions further validated Daxor’s BVA technology across critical, high-cost patient populations: Banner University Medical Center: New data confirms the urgent need for a focus on “volume re-calibration” in heart failure care. Patients with optimal total blood and red cell volume as measured by Daxor’s BVA test had zero unplanned hospital admissions, versus 57-77% for those with imbalances in either total blood or red blood cell volume. These findings prove objective BVA measurement reveals patients needing additional treatment to prevent readmissions. Wellstar Health System: The use of BVA-guided care pre- and post-LVAD implantation led to remarkable outcome improvements. The study showed substantially reduced severe acute kidney injury, one of the leading complications from LVAD procedures. Quantified results demonstrated this approach boosted 30-day survival from 90.3% to 93.6% and 1-year survival from 79.6% to 87.8%; cut 30-day readmissions from 28.6% to 18.5%; and decreased post-operative length of stay by 1.5 days. Geisinger Medical Center: New data confirms that patients with Cardiac Amyloidosis have significantly higher total blood and plasma volumes. BVA can help diagnose this unique CA phenotype, assisting clinicians with accurate diuretic dosing for better patient function.